Boston Research & Management Inc. Takes $317,000 Position in GE Vernova Inc. $GEV

GE Vernova reported quarterly revenue of $9.97 billion, up 11.8% year-over-year and ahead of the $9.15 billion consensus, but missed on EPS at $1.64 versus $1.72, leaving FY‑2025 guidance unspecified in the release; the stock was slightly down (‑0.4%) on the news. Institutional activity in Q2 shows modest new buys—Boston Research & Management bought 600 shares (~$317k) and several advisers increased small positions—while CFO Kenneth Scott Parks sold 3,300 shares at an average $620 for $2.05 million, cutting his stake by about 30%, with insiders holding 0.15% overall. Analysts remain broadly positive (consensus “Moderate Buy”, average target $607.81) after a string of price-target raises, and the company pays a modest $0.25 quarterly dividend (0.2% yield), leaving investors to balance top‑line momentum and analyst optimism against the EPS miss and notable insider selling.

Analysis

GE Vernova reported quarterly revenue of $9.97 billion, up 11.8% year‑over‑year and ahead of the $9.15 billion consensus, while EPS was $1.64 versus a $1.72 analyst estimate (a $0.08 miss); the company generated a net margin of 4.52% and a return on equity of 17.07%, and last year’s comparable quarter posted a ($0.35) EPS. The firm has set FY‑2025 guidance at EPS (as disclosed) but the release left some clarity gaps on full‑year cadence, and the stock was modestly lower (‑0.4%) on the news. Analyst reaction is largely constructive with four Strong Buy, 19 Buy, eight Hold and two Sell ratings, an average target of $607.81 and several recent upward price‑target revisions (e.g., Susquehanna $750, JPMorgan $740, GLJ $758) offset by a Mizuho cut to $660. Institutional flows in Q2 show small incremental purchases (Boston Research bought 600 shares for ~ $317k) while insider activity was notable: CFO Kenneth Scott Parks sold 3,300 shares at $620 for $2.046m, trimming his position ~30.3% and leaving insiders owning 0.15%. The company returned a $0.25 quarterly dividend (annualized $1.00, 0.2% yield; DPR 16.29%), indicating modest capital return relative to growth investments, so investors must balance resilient top‑line momentum and analyst optimism against the EPS miss and significant insider reduction in stake.

Key Decisions for Investors

• Consider a measured buy‑on‑weakness approach given 11.8% revenue growth and supportive analyst targets (avg $607.81), but size new positions conservatively because EPS missed and FY‑2025 guidance remains imprecise
• Monitor next two quarters for margin and EPS recovery (focus on net margin and ROE trends) and for corroborating institutional accumulation before increasing exposure
• Treat the CFO’s 3,300‑share sale at $620 as a cautionary signal—avoid full conviction until insider/institutional buying resumes or management provides clearer guidance, and use the low dividend yield as secondary to earnings momentum